FULC Q2 2024 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$80M+8990.9% YoY

Gross Profit

$63M78.4% margin

Operating Income

$52M65.6% margin

Net Income

$55M69.3% margin

EPS (Diluted)

$0.87

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$59M

Free Cash Flow

$59M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$294M

Total Liabilities

$20M

Stockholders' Equity

$274M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80M	$880,000	+8990.9%
Gross Profit	$63M	-$17M	+469.7%
Operating Income	$52M	-$27M	+292.3%
Net Income	$55M	-$24M	+333.0%